Journal of diabetes research · 2026
Development and Validation of an Integrated Metabolism-Obesity Index for Screening Renal Impairment in Patients With Newly Diagnosed Type 2 Diabetes Mellitus.
СтатьяВалидационное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhu Xiangying, Li Xinyuan, Wang Zhenhua, Ji Meixia, Ji Xiaoxiao, Jin Lihong, Zeng Chunlai, Gu Yuanliang
Аннотация
BACKGROUND: Diabetic kidney disease, a severe diabetes microvascular complication affecting 30%~40% of diabetic patients, raises end-stage renal disease and mortality risks. This study is aimed at developing and validate a novel index combining obesity measures and metabolic parameters to screen renal impairment in newly diagnosed T2DM patients.
METHODS: A total of 387 and 259 newly diagnosed T2DM patients were recruited for model development and validation, respectively. Renal impairment was defined as eGFR < 60 mL/min/1.73 m2 and/or urinary albumin-to-creatinine ratio (UACR) ≥ 30 mg/g. Obesity- or metabolism-related indicators were collected. Significantly independent indicators were selected via bidirectional stepwise regression in the modeling patients to develop a comprehensive index termed InMOI. In the validation patients, restricted cubic spline analysis examined the dose-response relationship between InMOI and renal impairment, whereas ROC curves assessed the screening performance.
RESULTS: The triglyceride-glucose index (TyG) combined with various obesity measures showed significant associations with renal impairment. The InMOI, derived from TyG-BMI and TyG-waist to hip ratio (TyG-WHR), demonstrated a linear dose-response relationship with the odds ratio for renal impairment. InMOI achieved an AUC of 0.78 for identifying renal impairment. Optimizing the index by replacing WHR with the visceral-to-subcutaneous fat area ratio measured by DEXA, the modified InMOI (m-InMOI) showed a better performance (AUC = 0.81).
CONCLUSION: This study underscores the value of metabolism-obesity indices in early detection of diabetic renal damage and highlights the pathogenic role of visceral obesity and metabolic dysregulation in diabetic kidney disease. The InMOI provides a practical tool for large-scale screening and early prevention of diabetic kidney disease.
METHODS: A total of 387 and 259 newly diagnosed T2DM patients were recruited for model development and validation, respectively. Renal impairment was defined as eGFR < 60 mL/min/1.73 m2 and/or urinary albumin-to-creatinine ratio (UACR) ≥ 30 mg/g. Obesity- or metabolism-related indicators were collected. Significantly independent indicators were selected via bidirectional stepwise regression in the modeling patients to develop a comprehensive index termed InMOI. In the validation patients, restricted cubic spline analysis examined the dose-response relationship between InMOI and renal impairment, whereas ROC curves assessed the screening performance.
RESULTS: The triglyceride-glucose index (TyG) combined with various obesity measures showed significant associations with renal impairment. The InMOI, derived from TyG-BMI and TyG-waist to hip ratio (TyG-WHR), demonstrated a linear dose-response relationship with the odds ratio for renal impairment. InMOI achieved an AUC of 0.78 for identifying renal impairment. Optimizing the index by replacing WHR with the visceral-to-subcutaneous fat area ratio measured by DEXA, the modified InMOI (m-InMOI) showed a better performance (AUC = 0.81).
CONCLUSION: This study underscores the value of metabolism-obesity indices in early detection of diabetic renal damage and highlights the pathogenic role of visceral obesity and metabolic dysregulation in diabetic kidney disease. The InMOI provides a practical tool for large-scale screening and early prevention of diabetic kidney disease.